|
|
The effect of alendronate sodium on alveolar bone loss in
periodontitis (clinical trial).
El-Shinnawi UM, El-Tantawy SI.
Department of Oral Medicine and Periodontology, Faculty of Dentistry, Mansoura
University, Mansoura, Egypt. [email protected]
Alendronate sodium is a potent inhibitor of bone resorption which has been
effectively used to control osteolysis, and to treat Paget's disease and
osteoporosis. The objective of this study was to investigate the effect of
alendronate sodium, systemically induced in the treatment of patients with
periodontitis. Twenty-four adult periodontitis patients were included in the
study (for six months) and were divided into two groups. Group I, included
twelve patients who received one tablet of fosamax (alendronate sodium, MSD)
every morning for six months. Group II, also included twelve patients who
received no drug during the study period. All patients received initial
periodontal therapy. Bone mineral density (BMD) of the maxilla and mandible was
measured for all subjects using a dual energy absorptiometer (DEXA) at the
beginning of the study and at the end of six months using DPX. MD Scanner.
Clinical periodontal measurements were carried out for all patients at the
initial appointment and six months later in the form of pocket depth, attachment
level and gingival index. A statistically significant difference in bone density
(P < 0.001) was observed favouring the alendronate group (Group I). Alendronate
sodium had no effect on the clinical parameters and could play an important role
as an adjunct to conventional periodontal therapy in management of periodontal
diseases.
Publication Types:
- Clinical Trial
- Randomized Controlled Trial
PMID: 12666950 [PubMed - indexed for MEDLINE]
Sponsors' Ads by Google 以下為谷歌所提供贊助者之廣告
Last update: Mar 14, 2009;
9:15 a.m. LAH
|